Clinical Trials Logo

Prurigo clinical trials

View clinical trials related to Prurigo.

Filter by:

NCT ID: NCT03630198 Completed - Plaque Psoriasis Clinical Trials

Pain Outcomes Following Intralesional Corticosteroid Injections

Start date: October 1, 2018
Phase: Phase 4
Study type: Interventional

Corticosteroid therapy, including intralesional and topical applications, has many indications within the fields of Dermatology, Plastic Surgery, and Orthopedics. However, these injections can be quite painful, which leads many patients to discontinue treatment. Often, the injection involves a mixture of local anesthetic and corticosteroids despite a lack of evidence that the use of lidocaine improves pain. Due to the acidic pH, the lidocaine component of the injection can actually cause a significant burning sensation during the procedure. Lidocaine does not have anti-inflammatory properties and does not treat the underlying pathology. By including another medication, lidocaine also adds cost and risk to the procedure. The purpose of this study is to see if removing lidocaine from intralesional injections decreases the pain of injection.

NCT ID: NCT03546816 Completed - Pruritus Clinical Trials

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

Start date: May 2, 2018
Phase: Phase 3
Study type: Interventional

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

NCT ID: NCT03497975 Completed - Prurigo Nodularis Clinical Trials

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

PRISM
Start date: August 7, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

To investigate the anti-pruritic efficacy and safety of Nalbuphine Extended Release (ER) (NAL ER) tablets in Prurigo Nodularis. Subjects will be randomized to NAL ER (or matching placebo) with the primary endpoint evaluation at Week 14. During the open label extension, subjects who received NAL ER will continue on NAL ER and subjects who received placebo will crossover to NAL ER.

NCT ID: NCT03181503 Completed - Prurigo Nodularis Clinical Trials

Safety and Efficacy of Nemolizumab in PN

Start date: October 2, 2017
Phase: Phase 2
Study type: Interventional

The aim of this study is to assess the safety and efficacy of nemolizumab in subjects with prurigo nodularis.

NCT ID: NCT02196324 Completed - Prurigo Nodularis Clinical Trials

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Start date: July 9, 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.

NCT ID: NCT02174432 Completed - Prurigo Nodularis Clinical Trials

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Start date: August 15, 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of the study is to evaluate the overall safety of nalbuphine HCL ER tablets during a treatment period of up to 50 weeks.

NCT ID: NCT02174419 Completed - Pruritus Clinical Trials

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Start date: March 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objectives of the study are to evaluate the effects of two doses of nalbuphine HCl ER tablets on the change from baseline in the worst itch Numerical Rating Scale (NRS) in patients with prurigo nodularis and to evaluate the safety and tolerability in the study population.

NCT ID: NCT01963793 Completed - Pruritus Clinical Trials

Topical Aprepitant in Prurigo Patients

iTAPP
Start date: October 2013
Phase: Phase 2
Study type: Interventional

Topical Aprepitant in Prurigo Patients - An Exploratory Phase IIa Trial With Topically Applied Aprepitant in Patients With Prurigo

NCT ID: NCT00869089 Completed - Prurigo Nodularis Clinical Trials

Safety and Efficacy of CC-10004 for Prurigo Nodularis

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This trial will include: - Study period up to 7 months. - Office visits monthly lasting approximately 1 hour. - Blood Draws. - Oral medication that is taken 2 times daily. - Photographs and biopsies if agreed.

NCT ID: NCT00507832 Completed - Prurigo Nodularis Clinical Trials

Evaluation of the Antipruritic Effect of Elidel (Pimecrolimus) in Non-atopic Pruritic Disease

CASM981CDE21
Start date: April 2007
Phase: Phase 2
Study type: Interventional

The development of the topical calcineurin inhibitor pimecrolimus resulted in a significant improvement in the treatment of atopic dermatitis. In addition, an excellent amelioration of pruritus could be regularly observed. Up to now, several itchy dermatoses such as chronic irritative hand dermatitis, rosacea, graft-versus-host-disease, lichen sclerosus, prurigo simplex, scrotal eczema, and inverse psoriasis were reported as single cases also to respond to a pimecrolimus treatment. In prurigo nodularis, pruritus is the main symptom and it is of immediate importance to find an effective antipruritic therapy. Pruritus is regularly severe and therapy refractory to topical steroids or systemic antihistamines. Capsaicin cream is one effective possibility to reduce the itch in these diseases. However, it has to be applied 3 to 6 times daily, rubs off on the clothing and induces burning in erosions. In addition, since no commercial preparation is available, it has to be prescribed in several concentrations. The application of pimecrolimus seems to be promising since it has to be applied twice daily only. Especially in prurigo nodularis we expect a good response as we could demonstrate in single patients. Furthermore it has been published recently that Tacrolimus, another calcineurin inhibitor has been successfully used in the treatment of six patients with prurigo nodularis. This study is designed to compare the efficacy and safety of pimecrolimus 1% cream and hydrocortisone 1% cream in prurigo nodularis and to investigate the mode of action of the antipruritic effect of the drugs.